NanoString Technologies has appointed Kirk Malloy to its Board of Directors. Malloy brings 20 years of experience in the life science tools, applied markets, and molecular diagnostics markets. He is the founder of consulting firm BioAdvisors, and was previously senior VP and general manager of life sciences and applied markets at Illumina. Prior to that, Malloy worked at Biosite and Qiagen. He also sits on the boards of publicly traded Organovo Holdings and the privately-held firms Edico Genome, iGenomx, and Agilome.
In a filing with the US Securities and Exchange Commission last week, Fluidigm announced that Marc Unger, executive vice president of research and development and marketing, will be taking a 10-week leave of absence starting Oct. 1. The filing also stated that Unger and Fluidigm plan to enter into a part-time consulting agreement following Unger's leave. Both parties are still in discussions regarding details of the arrangement.
Analytik Jena has appointed current Chief Marketing and Sales Officer Ulrich Krauss as CEO, effective Oct. 1. Krauss will succeed founder Klaus Berka who will stay on to oversee the company's research and development efforts. Krauss has held various international management positions at the Carl Zeiss Group, most recently as the CEO of Carl Zeiss Vision. He has also served on the executive board of Carl Zeiss Meditec for over nine years.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.